REGEN-COV® for Treatment of Hospitalized Patients with Covid-19

Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P. Menon, Jason C. Wells, Shazia Ali, Sumathi Sivapalasingam, Yiping Sun, Rafia Bhore, Jingning Mei, Jutta Miller, Lisa Cupelli, Andrea T. Hooper, Jennifer D. Hamilton, Cynthia Pan, Viet Pham, Yuming Zhao, Romana Hosain, Adnan Mahmood, John D. Davis, Kenneth C. Turner, Yunji Kim, Amanda Cook, Bari Kowal, Yuhwen Soo, A. Thomas DiCioccio, Gregory P. Geba, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary A. Herman, George D. Yancopoulos, David M. Weinreich, for the Covid-19 Phase 2/3 Hospitalized Trial Team
doi: https://doi.org/10.1101/2021.11.05.21265656

Article Information

doi 
https://doi.org/10.1101/2021.11.05.21265656
History 
  • November 10, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Selin Somersan-Karakaya, M.D.1,†,*,
  2. Eleftherios Mylonakis, M.D., Ph.D.2,*,
  3. Vidya P. Menon, M.D.3,
  4. Jason C. Wells, M.D.4,
  5. Shazia Ali, Pharm.D.1,
  6. Sumathi Sivapalasingam, M.D.1,‡,
  7. Yiping Sun, Ph.D.1,
  8. Rafia Bhore, Ph.D.1,
  9. Jingning Mei, Ph.D.1,
  10. Jutta Miller, B.S., R.N.1,
  11. Lisa Cupelli, Ph.D.1,
  12. Andrea T. Hooper, Ph.D.1,
  13. Jennifer D. Hamilton, Ph.D.1,
  14. Cynthia Pan, B.Pharm.1,
  15. Viet Pham, B.S.1,
  16. Yuming Zhao, M.S.1,
  17. Romana Hosain, M.D., M.P.H.1,‡,
  18. Adnan Mahmood, M.D.1,
  19. John D. Davis, Ph.D.1,
  20. Kenneth C. Turner, Ph.D.1,
  21. Yunji Kim, Pharm.D.1,
  22. Amanda Cook, B.S., Dip.Reg.Aff1,
  23. Bari Kowal, M.S.1,
  24. Yuhwen Soo, Ph.D.1,
  25. A. Thomas DiCioccio, Ph.D.1,
  26. Gregory P. Geba, M.D., Dr.PH.1,
  27. Neil Stahl, Ph.D.1,
  28. Leah Lipsich, Ph.D.1,‡,
  29. Ned Braunstein, M.D.1,
  30. Gary A. Herman, M.D.1,
  31. George D. Yancopoulos, M.D., Ph.D.1,
  32. David M. Weinreich, M.D.1,
  33. for the Covid-19 Phase 2/3 Hospitalized Trial Team
  1. 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  2. 2Brown University, Providence, RI
  3. 3NYC Health + Hospitals/Lincoln, Bronx, NY
  4. 4The Oregon Clinic, Portland, OR
  1. ↵†Corresponding author: Selin Somersan-Karakaya, email: selin.somersan{at}regeneron.com

  1. ↵* Contributed equally

Back to top
Posted November 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email
REGEN-COV® for Treatment of Hospitalized Patients with Covid-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P. Menon, Jason C. Wells, Shazia Ali, Sumathi Sivapalasingam, Yiping Sun, Rafia Bhore, Jingning Mei, Jutta Miller, Lisa Cupelli, Andrea T. Hooper, Jennifer D. Hamilton, Cynthia Pan, Viet Pham, Yuming Zhao, Romana Hosain, Adnan Mahmood, John D. Davis, Kenneth C. Turner, Yunji Kim, Amanda Cook, Bari Kowal, Yuhwen Soo, A. Thomas DiCioccio, Gregory P. Geba, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary A. Herman, George D. Yancopoulos, David M. Weinreich, for the Covid-19 Phase 2/3 Hospitalized Trial Team
medRxiv 2021.11.05.21265656; doi: https://doi.org/10.1101/2021.11.05.21265656
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area